Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy
暂无分享,去创建一个
S. Harrison | K. Thursky | T. Spelman | M. Slavin | L. Worth | B. Teh | S. Harrison
[1] U. Mellqvist,et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients , 2015, Haematologica.
[2] S. Harrison,et al. Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies , 2015, Haematologica.
[3] S. Harrison,et al. Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital , 2014, Supportive Care in Cancer.
[4] M. Pellegrini,et al. Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection. , 2014, Blood reviews.
[5] R. Wäsch,et al. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients , 2014, Annals of Hematology.
[6] E. Bow. Infection in neutropenic patients with cancer. , 2013, Critical care clinics.
[7] Je-Jung Lee,et al. Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens , 2013, International Journal of Hematology.
[8] G. Tricot,et al. Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] C. Huff,et al. Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses , 2012, Clinical Cancer Research.
[10] E. Wood,et al. Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications , 2011, Annals of Hematology.
[11] M. Dimopoulos,et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. , 2011, Blood.
[12] I. Turesson,et al. Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. , 2010, Mayo Clinic proceedings.
[13] E. Anaissie,et al. Infections in patients with multiple myeloma. , 2009, Seminars in hematology.
[14] K. Anderson,et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma , 2009, Leukemia.
[15] Patricia Muñoz,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] Margaret A Dudeck,et al. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. , 2008, American journal of infection control.
[17] S. Seeber,et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections , 2006, Leukemia & lymphoma.
[18] G. Morgan,et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] B. Cunha,et al. Infections associated with steroid use. , 2001, Infectious disease clinics of North America.
[20] H. Fukuda,et al. European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .
[21] H. Chapel,et al. Immunological factors and risk of infection in plateau phase myeloma. , 1995, Journal of clinical pathology.
[22] J. Karp,et al. From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. , 1990, The Journal of infectious diseases.
[23] M. Oken,et al. Influence of treatment and response status on infection risk in multiple myeloma. , 1981, The American journal of medicine.
[24] R. Fonseca,et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. , 2010, The Lancet. Oncology.
[25] V. Rossi,et al. Risk factors for the development of bacterial infections in patients with multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules , 2003 .
[26] V. Rossi,et al. Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules. , 2003, Haematologica.
[27] H. Einsele,et al. Definitions of infectious diseases and complications after stem cell transplant , 2002 .
[28] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[29] H. Birgens,et al. Current patterns of bacterial infection in myelomatosis. , 1984, Scandinavian journal of infectious diseases.